UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to __________ Commission file number 1-38519 AgeX Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 82-1436829 (State or othe ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to __________ Commission file number 1-38519 AgeX Therapeutics, Inc. | Title of each class | Trading Symbol | Name of exchange on which registered | | -- ...

Financial Performance - Operating losses for the years ended December 31, 2019 and 2018 were $12.6 million and $11.2 million, respectively, with an accumulated deficit of $86.2 million as of December 31, 2019[337]. - Total revenues for the year ended December 31, 2019, were $1.728 million, an increase of 23.8% from $1.396 million in 2018[384]. - Subscription and advertising revenues increased by 8.6% to $1.332 million in 2019 from $1.227 million in 2018[384]. - Grant revenues rose significantly to $180,000 in 2019 from $20,000 in 2018, reflecting a $160,000 increase[384]. - Other revenues increased by 45.0% to $216,000 in 2019 from $149,000 in 2018[384]. - Gross profit for 2019 was $1.484 million, a 43.8% increase from $1.032 million in 2018[384]. - Net loss attributable to the company for the year ended December 31, 2019, amounted to $12.2 million, with net cash used in operating activities totaling $10.2 million[416]. - The accumulated deficit as of December 31, 2019, was $86.2 million, indicating ongoing operating losses and negative cash flows since inception[410]. - The company experienced recurring losses and negative operating cash flows since inception, indicating ongoing financial challenges[423]. Research and Development - The biotechnology company focuses on developing therapeutics targeting human aging and degenerative diseases, with initial programs aimed at diabetes, obesity, and heart disease[335]. - The company has incurred significant expenses related to research and development, including personnel costs, stock-based compensation, and outside consultants[346]. - Research and development expenses decreased by $0.7 million to $5.9 million in 2019, primarily due to the non-recurrence of a $0.8 million in-process research and development expense from 2018[392]. - Total research and development expenses, including acquired in-process research and development, amounted to $5.9 million in 2019, down from $6.6 million in 2018[394]. Operational Challenges - Significant operating losses are expected to continue for the foreseeable future, necessitating additional financing to support operations and research and development programs[337]. - The company expects to continue incurring significant expenses and operating losses, indicating a need for ongoing capital resources[337]. - The company anticipates that its cash and cash equivalents will not be sufficient to meet anticipated operating and funding requirements for the next twelve months[411]. - Management plans to implement a Restructuring Plan if borrowing exceeds $500,000, which may lead to significant staff reductions and impact future operations[383]. - The company expects to borrow an initial $500,000 under a new loan agreement, but additional loans are subject to discretion, raising concerns about future funding[412]. Revenue Sources - The company has not generated any revenue from product sales and relies on subscription and advertising revenue from LifeMap Sciences' online databases[336]. - LifeMap Sciences' revenues are primarily derived from its GeneCards online database, with no products approved for sale[382]. - As of December 31, 2019, $0.3 million was included in deferred revenues, expected to be recognized as subscription revenue over the next twelve months[377]. Expenses - General and administrative expenses increased by $2.5 million to $8.1 million in 2019, with significant contributions from professional fees ($1.0 million) and insurance premiums ($0.8 million)[399]. - General and administrative expenses for LifeMap Sciences accounted for 10.2% of total expenses in 2019, down from 14.9% in 2018[397]. - Non-cash items affecting net loss included $1.9 million in stock-based compensation and $1.0 million in depreciation and amortization[416]. Financial Position - The company recorded a gain of $354,000 on the sale of its Ascendance common stock in 2019, following a previous gain of $3.2 million in 2018[401]. - The company has established a full valuation allowance for deferred tax assets due to uncertainty in realizing future tax benefits[409]. - The company had no off-balance sheet arrangements as of December 31, 2019[419]. - The financial statements were audited and presented fairly in all material respects for the years ended December 31, 2019, and 2018[422]. - The company utilizes the Black-Scholes option pricing model for estimating the fair value of stock options granted under its equity incentive plan[356]. - The Shared Facilities and Services Agreement with Lineage terminated on September 30, 2019, ending the provision of services and facilities[344].

Revenue Growth - Total revenues for the three months ended September 30, 2019, increased by 8.2% to $411,000 compared to $380,000 in the same period of 2018[114] - Subscription and advertising revenues for the nine months ended September 30, 2019, rose by 5.0% to $992,000 from $945,000 in 2018[116] - Grant revenues recognized during the three and nine months ended September 30, 2019, were $41,000 and $103,000, respectively, with no grant revenue in the same periods of 2018[117] - Gross profit for the nine months ended September 30, 2019, increased by 12.8% to $1,014,000 compared to $899,000 in the same period of 2018[114] - The company reported a gross profit margin of approximately 86.5% for the nine months ended September 30, 2019, compared to 83.0% in the same period of 2018[114] Expenses - Research and development expenses for the three months ended September 30, 2019, increased by 8.6% to $1,447,000 compared to $1,332,000 in 2018[122] - General and administrative expenses for the three months ended September 30, 2019, surged by 75.0% to $2,194,000 from $1,254,000 in 2018[122] - Total general and administrative expenses for the nine months ended September 30, 2019, were $6,422,000, a 74.6% increase from $3,679,000 in 2018[129] - Research and development expenses for the nine months ended September 30, 2019, decreased by 13.2% to $4,435,000 from $5,107,000 in 2018, primarily due to the non-recurrence of in-process research and development expenses[124] - General and administrative expenses for the nine months ended September 30, 2019 increased by $2.7 million to $6.4 million compared to $3.7 million during the same period in 2018[131] Financial Position - Total research and development expenses for the nine months ended September 30, 2019 were $4.4 million, while net loss attributable to the company amounted to $9.4 million[142] - Net cash used in operating activities during the nine months ended September 30, 2019 was $7.7 million, with a difference primarily due to non-cash items including $1.5 million in stock-based compensation[142] - Cash provided by financing activities amounted to $5.0 million, which included $4.5 million from the exercise of warrants to purchase 1,800,000 shares of common stock[144] - The company had an accumulated deficit of $83.5 million as of September 30, 2019, and expects to continue incurring operating losses and negative cash flows[138] - As of September 30, 2019, cash and cash equivalents were $3.8 million, which, along with a potential $1.5 million loan facility, may not be sufficient to meet anticipated operating requirements for the next twelve months[140] Other Financial Activities - The company recognized a gain of $354,000 on the sale of its Ascendance common stock during the nine months ended September 30, 2019[133] - The Shared Facilities Agreement with Lineage terminated on September 30, 2019, leading to increased expenses related to new office and laboratory facilities[139] - A foreign income tax provision of $130,000 was recorded for the nine months ended September 30, 2019, primarily due to foreign currency transaction gains[136] - The company established a full valuation allowance for all domestic deferred tax assets due to uncertainty in realizing future tax benefits[137]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from___________ to __________ Commission file number 1-38519 AgeX Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 82-1436829 (State or other ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (I.R.S. Employer Identification No.) FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from___________ to __________ Commission file number 1-38519 AgeX Therapeutics, Inc. (Exact name of registrant as specified in its charte ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from___________ to __________ Commission file number 1-38519 AgeX Therapeutics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorpo ...